Incyte

Quality 0.50 · 2 views · Updated 2 months ago

American pharmaceutical company

title: "Incyte" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["american-companies-established-in-1991", "companies-based-in-new-castle-county,-delaware", "pharmaceutical-companies-established-in-1991", "companies-listed-on-the-nasdaq", "1991-establishments-in-california", "pharmaceutical-companies-of-the-united-states", "life-sciences-industry", "health-care-companies-based-in-delaware", "1993-initial-public-offerings"] description: "American pharmaceutical company" topic_path: "law" source: "https://en.wikipedia.org/wiki/Incyte" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary American pharmaceutical company ::

::data[format=table title="Infobox company"]

FieldValue
nameIncyte Corporation
logoIncyte logo.svgclass=skin-invert-image
typePublic
traded_as
founded
founderRoy A. Whitfield
defunct
location_cityWilmington, Delaware, U.S.
key_peopleBill Meury (CEO & president)
industrypharmaceuticals
revenue(2024)
operating_incomeUS$61.4 million (2024)
net_incomeUS$32.6 million (2024)
assetsUS$5.44 billion (2024)
equityUS$3.45 billion (2024)
num_employees2,617
num_employees_year2024
website
footnotes
::

| name = Incyte Corporation | logo = Incyte logo.svgclass=skin-invert-image | caption = | type = Public | traded_as = | fate = | predecessor = | successor = | founded = | founder = Roy A. Whitfield | defunct = | location_city = Wilmington, Delaware, U.S. | location_country = | locations = | area_served = | key_people = Bill Meury (CEO & president) | industry = pharmaceuticals | products = | services = | revenue = (2024) | operating_income = US$61.4 million (2024) | net_income = US$32.6 million (2024) | assets = US$5.44 billion (2024) | equity = US$3.45 billion (2024) | owner = | num_employees = 2,617 | num_employees_year = 2024 | parent = | divisions = | subsid = | website = | footnotes =

Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.

Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.

History

In June 2025, Incyte named Bill Meury president, CEO, and a member of the board of directors. He replaced Hervé Hoppenot, who retired after 11 years of service.

In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million.

In January 2020, Incyte signed a collaboration and license agreement for the global development and commercialization of tafasitamab with MorphoSys. On March 3, 2020, the agreement received antitrust clearance and thus became effective.

Incyte established a European headquarters in Morges, Switzerland, in 2021.

Pharmaceuticals

Incyte Corporation currently has seven marketed and co-marketed pharmaceutical products, including Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix), Opzelura (Ruxolitinib), Tabrecta (capmatinib), Olumiant (Baricitinib), and Iclusig (ponatinib). In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is marketed under the brand name Tabrecta.

As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly. It gained EU approval in February 2017. In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety. In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis under the brand name Olumiant.

As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo).

Acquisition history

Incyte has made a total of 3 acquisitions.

  • Maxia Pharmaceuticals (2003): An early acquisition in Incyte's history, the company purchased Maxia in 2003 for $42 million.
  • Villaris Therapeutics (2022): This acquisition was valued at approximately $1.4 billion and included an upfront payment along with milestones. It added new assets to Incyte's portfolio for treating vitiligo and other autoimmune conditions.
  • Escient Pharmaceuticals (2024): In May 2024, Incyte acquired this San Diego-based, clinical-stage company for $750 million. The acquisition provided Incyte with two oral drug candidates for inflammatory diseases, EP262 and EP547.

References

References

  1. (February 10, 2025). "Incyte Corp. 2024 Annual Report (Form 10-K)". [[U.S. Securities and Exchange Commission]].
  2. "INCY".
  3. "Headquarters - Pharmaceutical Research & Development {{!}} Incyte".
  4. https://investor.incyte.com/news-releases/news-release-details/incyte-appoints-bill-meury-chief-executive-officer-herve
  5. (2 September 2015). "Incyte to Co-Develop Hengrui's SHR-1210 in Up-to-$795M+ Deal". Genetic Engineering & Biotechnology News.
  6. "MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab".
  7. "MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab".
  8. (15 July 2020). "Incyte to establish European headquarters in Geneva".
  9. "incy_Current folio_10K".
  10. "portfolio.pdf".
  11. (29 April 2013). "Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development {{!}} Business Wire".
  12. (9 Dec 2014). "Lilly, Incyte Treatment Shows Positive Results".
  13. "Baricitinib". American Medical Association.
  14. (16 March 2017). "Olumiant: Authorisation details". [[European Medicines Agency]].
  15. Ramsey, L. (17 April 2017). "The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling". Business Insider.
  16. Grant, Ch. (14 April 2017). "Surprise FDA Rejection Will Sting This Biotech". The Wall Street Journal.
  17. Research, Center for Drug Evaluation and. (2019-02-09). "Drug Trials Snapshots: OLUMIANT". FDA.
  18. "Drug Approval Package: Olumiant (baricitinib)".
  19. (May 2017). "The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.". European Journal of Cancer.
  20. Tracy Staton. (Apr 3, 2017). "Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials". FiercePharma.
  21. (February 19, 2003). "Incyte Acquires Maxia Pharmaceuticals; Acquisition Expands Drug Discovery & Development Programs {{!}} Incyte".
  22. (October 3, 2022). "Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6) {{!}} Incyte".
  23. "Incyte Completes Acquisition of Escient Pharmaceuticals {{!}} Incyte".

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::

american-companies-established-in-1991companies-based-in-new-castle-county,-delawarepharmaceutical-companies-established-in-1991companies-listed-on-the-nasdaq1991-establishments-in-californiapharmaceutical-companies-of-the-united-stateslife-sciences-industryhealth-care-companies-based-in-delaware1993-initial-public-offerings